In 2018 Polycrystalline created a parent company: PolyCrystalLine CDMOThis new division will be ready in the Q3 of 2022 and it will be a Contract Development and Manufacturing Organization (CDMO) cGMP certified and  specialized in helping pharma companies to connect our legacy of experience in solid state chemistry with their requirements for innovation, commercial manufacturing and product success.


PolyCrystalLine CDMO
borns from the evolution of PolyCrystalLine, which after 15 years of experience in the development and optimization of APIs crystallization decided to combine its know-how in solid-state chemistry with cGMP process development and optimization, up to kilograms supply of cGMP APIs and HPAPIs

Starting from Q3 of 2022, PolyCrystalLine CDMO will offer a comprehensive portfolio of solutions to fully control and understand your process, thus enabling consistent, robust production of cGMP quality products.